Our Solution
EDY diagnostics develops a standardized and scalable multiplex in vitro diagnostic platform that can test up to 100 biomarkers in parallel. The assay is easy-to-use and detects cancer-specific antibodies in blood with high accuracy.
Accurate Diagnostics
Our platform is designed to deliver precise results, ensuring that physicians can make informed decisions for their patients.
Efficient Workflow
Unlike solid-phase solutions, our suspension array offers a high degree of multiplexing and throughput, saving time, labour and materials.
Seamless Integration
The test integrates effortlessly into existing practice - no additional setup, training, or investment required. With just a simple blood draw.
Our First Product
Each year, millions of people receive their cancer diagnosis too late. Late diagnosis is particularly common in oropharyngeal cancer caused by HPV.
Around two-thirds of all cases are detected at an advanced cancer stage. For many, this means surgery, radiation and chemotherapy; treatments that often lead to swallowing and speech disorders, dry mouth and loss of taste, accompanied by social isolation and an increased risk of suicide.
But it doesn't have to be that way. An early diagnosis paves the way for less intensive therapies, in many cases eliminating the need for chemotherapy and ensuring patients retain a high quality of life.
This is where our assay comes in. The test detects cancer-specific HPV antibodies in blood long before clinical signs are clearly evident – with high accuracy even in early stages.
Our Team
Daniela, Julia, and Lea are renowned experts in tumor research. They have collaborated for over ten years, bringing a wealth of experience and deep understanding to their work. Christian complements their expertise with more than ten years of commerical experience in the life science industry.
Our Supporting Network
